Otsuka to Present Pivotal Two-Year eGFR Results from the Phase 3 VISIONARY Trial of VOYXACT® (sibeprenlim

Submitted by Anonymous on

INDICATION and IMPORTANT SAFETY INFORMATION for VOYXACT® (sibeprenlimab-szsi) INDICATION VOYXACT is indicated to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk for disease progression. This indication is approved under accelerated approval based on reduction of proteinuria....

Otsuka to Present Pivotal Two-Year eGFR Results from the Phase 3 VISIONARY Trial of VOYXACT® (sibeprenlimab-szsi) in IgA Nephropathy (IgAN) at GlomCon Hawaii 2026

Submitted by Anonymous on

PRINCETON, N.J.--(BUSINESS WIRE)--Jul 27, 2026-- Otsuka Pharmaceutical Development & Commercialization, Inc. (Otsuka), announces that new data from the Phase 3 VISIONARY study will be presented at the GlomCon Hawaii 2026 conference taking place August 3-7, 2026. Building on recently reported...

Otsuka to Present Pivotal Two-Year eGFR Results from the Phase 3 VISIONARY Trial of VOYXACT® (sibeprenlimab-szsi) in IgA Nephropathy (IgAN) at GlomCon Hawaii 2026

Submitted by Anonymous on

PRINCETON, N.J.--(BUSINESS WIRE)--Otsuka Pharmaceutical Development & Commercialization, Inc. (Otsuka), announces that new data from the Phase 3 VISIONARY study will be presented at the GlomCon Hawaii 2026 conference taking place August 3-7, 2026. Building on recently reported topline results, the...

Stephen V Liu: MARIPOSA Shows Delayed Symptomatic Progression in EGFR-Mutant NSCLC

Submitted by Anonymous on

Stephen V Liu: MARIPOSA Shows Delayed Symptomatic Progression in EGFR-Mutant NSCLC Stephen V Liu, Associate Professor of Medicine at Georgetown Lombardi Comprehensive Cancer Center, shared on X:. “Report on time to symptomatic progression from phase III MARIPOSA study in EGFR...

Drug-specific timing and fatality patterns of EGFR-TKI-associated interstitial lung disease in NSCLC-related JADER reports

Submitted by Anonymous on

Abstract Interstitial lung disease (ILD) is a toxicity of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs). We characterized agent-specific fatality and timing patterns in the Japanese Adverse Drug Event Report database (JADER). We analyzed March 2026 JADER reports accepted...

Aflatoxin B1 Induces Anxiety-related Neurotoxicity Through Brain-region-Specific EGFR/AKT Signaling: Evidence from Integrative Network Toxicology and Mendelian Randomization

Submitted by Anonymous on

Abstract Aflatoxin B1 (AFB1) is a widespread foodborne mycotoxin with well-established hepatotoxic and carcinogenic effects; however, its potential role in neuropsychiatric disorders remains unclear. Emerging evidence suggests that AFB1 can cross the blood-brain barrier, inducing oxidative stress and neuronal dysfunction....

Corticosteroid-responsive portal lymphadenopathy mimicking malignant progression induced by furmonertinib in EGFR-mutated NSCLC: a case report

Submitted by Anonymous on

BackgroundThird-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are widely used in the treatment of NSCLC with EGFR mutati Abstract Background: Third-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are widely used in the treatment of NSCLC with...

The relationship of EBER, EGFR, p16, and E-cadherin expressions with epithelial-mesenchymal transition and tumor budding in laryngeal squamous cell carcinoma

Submitted by Anonymous on

AbstractObjective Laryngeal squamous cell carcinoma (LSCC) is a tumor characterized by high biological heterogeneity. According to our literature review, this study is the first to analyze the expression profiles of EGFR, p16, E-cadherin, and EBER in combination with epithelial–mesenchymal transition...

Subscribe to Newsfeed